Cincinnati Children’s is a nationally ranked pediatric health system and a recognized leader in both pediatric and adult research. With a legacy of impact spanning more than 90 years—from Albert Sabin’s oral polio vaccine to pioneering discoveries in lung surfactant proteins—we continue to advance science that improves lives. As one of the largest pediatric research institutions in the U.S., we secure $300 million in external research funding annually and play a central role in shaping the future of biomedical innovation. Innovation is embedded in our culture. One-third of our 19,000 employees are engaged in research and innovation across a broad spectrum of life sciences. From breakthrough therapeutic candidates and biotech platforms to diagnostics, medical devices, software, and research tools, our teams are building a pipeline of technologies with the potential for real-world impact. Explore our innovation portfolio and partnership opportunities at cincinnatichildrens.org/innovation-ventures.
ChomiX Biotech Co., Ltd.
The mission of ChomiX Biotech is to meet the unmet demands in the realms of biopharmaceuticals and precision medicine, through the development and provision of cutting-edge technologies in the areas of small molecule drugs, chemoproteomics, and drug discovery. | ChomiX Biotech is the first platform-based drug discovery company in China powered by live-cell chemoproteomics. The company specializes in drug screening in live-cell systems and the discovery of novel targets for bioactive drug molecules. Positioned as a “High-Value Drug Discovery Engine,” ChomiX Biotech adopts a dual-engine strategy combining platform partnerships and internal pipeline development. Leveraging its proprietary platform technologies, the company continuously advances drug discovery programs to demonstrate platform value, while engaging in deep collaborations with global pharmaceutical and biotech partners through out-licensing and co-development of internally developed pipelines.
CH Kilger, Patent & Trademark Attorneys
An International Approach With its head office in Berlin, branch offices in Munich and Buenos Aires CH KILGER offers a truly international approach providing a global IP service to its clients. The Munich office serves also for the preparation of the frequent oral proceedings CH KILGER takes part in. In Buenos Aires CH KILGER coordinates its Latin America services. The patent attorneys are highly specialized and strategic in their approach. A Wingspan of Expertise CH KILGER provides IP services ranging from trademark and patent prosecution, patent infringement and litigation, due diligence work, freedom-to-operate analyses, to opinion work and IP-sales/licensing transactions. CH KILGER can assist you in all technical areas such as the chemical, electrical, nanotechnology, food, biotechnology and pharmaceutical or the engineering fields. Strong scientific backgrounds, as well as years of legal experience working with the European Patent Office, the Latin American patent offices, top-tier international law firms and in-house counsel, mean the CH KILGER lawyers understand their technical, business, and legal goals. Our interdisciplinary approach leads to best possible synergies for our clients. Our Clients and Colleagues CH KILGER represents an international clientele of inventors as well as investors working with the most recent high-tech technologies. The clients range from multinational pharmaceutical corporations to start ups in various fields such as nanotechnology, microfluidics, polymer chemistry and biotechnology. Clients and colleagues have praised the firm for its exquisite work.
Certest Biotec
Certest Biotec, established in Spain in 2002 as an innovative and technology-based company, has always based its growth on the research and development of new products, and the exploration for new market niches and opportunities. The key to understand its success is the way to understand its organization: highly specialized and customer oriented. Certest Pharma part of Certest Biotec, is dedicated to building a platform for the development of RNA vaccines and oligotherapeutics, with a special focus on seeking improved formulations to enhance delivery. In that sense, Certest Pharma is specialized in the development of raw materials, amongst which lipids and more specifically, ionizable lipids, are one of the leading products. Certest´s Pharma three main areas are: Delivery technology: Ionizable lipids are a key element in the production of lipid nanoparticles (LNPs), and as such, have been widely used for the systemic delivery of RNA therapeutics. After the screening of more than a thousand ionizable lipids with our semi-rational design we are able to offer outperforming and custom made ionizable lipids for the effective targeted delivery of RNA therapeutics. API platform: This platform will cover, thanks to over 20 years of experience in the field, all the necessary steps for the design, development, and evaluation of effective mRNA and oligotherapeutics molecules. Also, a proprietary UTR sequence and codon optimization software have been developed showing higher results in protein expression. Enzymes for the production of mRNA have also been developed. Therapeutic products: Bringing together both areas Certest was granted to develop a new booster for TB vaccine and therefore be able to show the full capabilities of the company.
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first and is committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, Castle’s innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions. Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Using its expertise in advanced technologies, such as genomics, spatialomics, data analytics and artificial intelligence, Castle digs deep into treatment pathways to develop personalized, clinically actionable tests that can improve, and potentially transform, the management of diseases and patient outcomes. | At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
CancerFree Biotech
CancerFree Biotech has a patented system to create patient-derived organoids (PDO) using a bionic tumor culture system, which can be used as an avatar to help physicians and patients develop the optimal cancer treatment strategy. The technology uses blood specimens, making it easy and non-intrusive, and has been successful in deriving 130+ different types of solid tumors from real-world cancer patients. CancerFree Biotech is also collaborating with pharmaceutical companies, using their PDO model to predict clinical trial outcomes during the drug development process, potentially helping to validate compounds during the preclinical and clinical trial phases. | CancerFree Biotech has developed a proprietary cancer cell culture system called E.V.A. (Ex Vivo Avatar). E.V.A. combines 3D cell culture scaffolding with AI image recognition to facilitate tumor cell proliferation. Using just 20mL of patient blood, the platform grows tumor cells to generate heterogeneous organoid models that closely mimic the patient’s internal tumor. These models allow pharmaceutical companies to identify the best candidates for clinical trials by validating the efficacy of their drugs in suppressing tumor cells from real patients. | CancerFree Biotech has developed Prometheus Lab AI, a smart-glasses platform that automates R&D lab documentation. With hands-free, real-time workflow capture, Prometheus converts visual input into structured experiment records, reducing manual errors and significantly cutting down on documentation time.
Brazilian Center for Research – CNPEM
CNPEM is a sophisticated and ebullient environment for research and development that is the only one of its kind in Brazil and found in only a few scientific centers in the world. The Center private, non-profit organization overseen by the Ministry of Science, Technology, and Innovation (MCTI). The Center is home to Sirius, the most complex project in Brazilian science and one of the world’s most advanced synchrotron light sources. CNPEM comprises highly specialized multi-thematic teams, globally competitive lab infrastructure that is open to the scientific community, strategic lines of research, innovative projects in partnerships with the productive sector, and training programs for researchers and students. CNPEM is an environment driven by research into solutions that impact the areas of health, energy and renewable materials, agro environmental and engineering. | The Brazilian Center for Research in Energy and Materials (CNPEM) is home to a state-of-the-art, multi-user and multidisciplinary scientific environment. A social organization overseen by the Ministry of Science, Technology and Innovation, CNPEM powers Brazil’s science with cutting-edge labs like Sirius, tackling global challenges in health, renewable materials, energy & sustainability.
biotechrabbit GmbH
biotechrabbit is determined to offer the best products and services to those who lead the way in research. The valued relationships with our partners and customers drive us to exceed current limitations with flexibility, innovation and highly customized solutions to match their specific requirements. Each member of our team of highly engaged scientists, experienced managers and talented business developers aims to facilitate our partners and customers to leap and lead progress in the life science. Covering the whole workflow from enzyme production, ReadyMix development and lyophilization, biotechrabbit is the partner of choice for supplying molecular biology enzymes, reagents and mixes to diagnostics and life sciences. Our way of doing business combines the passion and pure curiosity of excellent researchers with the agile spirit of true entrepreneurs. | Covering the whole workflow from enzyme production, ReadyMix development and lyophilization, biotechrabbit is the partner of choice for supplying molecular biology enzymes, reagents and mixes to diagnostics and life sciences. biotechrabbit is determined to offer the best products and services to those who lead the way in research. The valued relationships with our partners and customers drive us to exceed current limitations with flexibility, innovation and highly customized solutions to match their specific requirements. Each member of our team of highly engaged scientists, experienced managers and talented business developers aims to facilitate our partners and customers to leap and lead progress in the life science. Our way of doing business combines the passion and pure curiosity of excellent researchers with the agile spirit of true entrepreneurs.
BIOSYNTH
Securing Life Sciences Supply Chains – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer-focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capabilities run across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Supplying the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. | Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer-focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capabilities run across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Supplying the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Find out more at www.biosynth.com. | Securing Life Sciences Supply Chains – where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivalled research product portfolio and end-to-end manufacturing services, we are science led and customer focused to solve problems and deliver key reagents at scale and quality. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is an innovative life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than half a million products in our research catalog and hundreds of complex manufacturing service projects. Our complex chemistry specialties include enzyme substrates, carbohydrate and nucleoside chemistry, with manufacturing services from the first idea to the finished product, from route scouting to GMP or ton scale production. For peptides, we also have a full end-to-end offering, from lead discovery and optimization, library production, through to GMP NCE or Neoantigen projects. Across biologics we have a synergistic offering, with an extensive range of custom bioprocessing enzyme projects for production of key products. We are also able to offer custom antibody projects, and epitope mapping. Through the Biosynth group we also offer development of antibodies, antigens and supply of plasma for in vitro diagnostics. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. Our main chemical research and manufacturing laboratories are in Switzerland, the United Kingdom, Slovakia and China, with peptide production in the USA and the Netherlands. Enzyme projects are based in Austria and biological IVD reagents in Ireland. Our R&D resources and production facilities are modern and versatile, allowing us to produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale.